Subtype
Extrapulmonary Neuroendocrine Carcinoma
CI-CAN-00002658Explore in graph →
104 active trials6 approved drugs22 evidence items
- NCIt
- C191977
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002658Explore in graph →
Clinical trials
315 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (50)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05013099 | Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies(iPREDICT) | unknown | Phase 2 | 70 | ImaginAb, Inc.INDUSTRY | 6 | Jul 22, 2024 | clinicaltrials |
| NCT05675605 | A Study of TY-1091 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 248 | TYK Medicines, IncINDUSTRY | 1 | Jan 30, 2024 | clinicaltrials |
| NCT05329792 | L19IL2/L19TNF in Skin Cancer Patients(IntriNSiC) | unknown | Phase 2 | 70 | Philogen S.p.A.INDUSTRY | 3 | Oct 6, 2023 | clinicaltrials |
| NCT05278364 | Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 184 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05429866 | Immunological Variables Associated to ICI Toxicity in Cancer Patients | unknown | Phase 2 | 441 | Jules Bordet InstituteOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT03787602 | Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma | unknown | Phase 1 / Phase 2 | 115 | Kartos Therapeutics, Inc.INDUSTRY | 10 | Mar 2, 2023 | clinicaltrials |
| NCT04787328 | A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC) | unknown | Phase 2 | 30 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Feb 23, 2022 | clinicaltrials |
| NCT04635956 | Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas | unknown | Phase 2 | 20 | Lei LiOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT03811379 | Toripalimab as Monotherapy for Patients With Small Cell Carcinoma of Esophagus Who Failed Chemotherapy | unknown | Phase 2 | 43 | Sun Yat-sen UniversityOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT02215447 | A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas(NABNEC) | unknown | Phase 2 | 4 | Barwon HealthOTHER_GOV | 1 | Nov 22, 2017 | clinicaltrials |
| NCT02409849 | Octreotide LAR as Maintenance Treatment for Patients With NEC | unknown | Phase 2 | 92 | Peking UniversityOTHER | 1 | Apr 7, 2015 | clinicaltrials |
| NCT01739634 | The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer | unknown | Phase 1 / Phase 2 | 10 | Salient Pharmaceuticals IncorporatedINDUSTRY | 1 | Dec 3, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Jul 22, 2024source: clinicaltrials